Cat# : THP-0018
|Description:||The product, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci.|
|Molecular Weight:||47286.7 Da|
|Endotoxin Level:||<0.001 EU per 1 μg by the LAL method|
|Applications:||For the treatment of acute evolving transmural myocardial infarction, pulmonary embolism, deep vein thrombosis, arterial thrombosis or emolism and occlusion of arteriovenous cannulae|
|Examples of Clinical Use:||Acute evolving transmural myocardial infarction, pulmonary embolism, deep vein thrombosis, arterial thrombosis or emolism and occlusion of arteriovenous cannulae|
|Pharmacodynamics:||The product creates an active complex which promotes the cleavage of the Arg/Val bond in plasminogen to form the proteolytic enzyme plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. This helps eliminate blood clots or arterial blockages that cause myocardial infarction.|
|Mechanism of action:||Plasminogen is an inactive molecule that becomes activated to plasmin when the Arg/Val bond is cleaved. Plasmin breaks down fibrin clots created by the blood clotting cascade. Streptokinase forms a highly specific 1:1 enzymatic complex with plasminogen which converts inactive plasminogen molecules into active plasmin. Plasmin degrades fibrin clots as well as fibrinogen and other plasma proteins. This in turn leads to the degradation of blood clots.|
|Affected organisms:||Humans and other mammals|
|Targets:||Target 1. Plasminogen; Target 2. Proteinase-activated receptor 1; Enzyme 1. Cytosolic phospholipase A2|
For more information on how our products could help advance your project, please contact us.
ENTER YOUR EMAIL HERE TO SUBSCRIBE.
Copyright © Creative BioMart. All Rights Reserved.